BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22343673)

  • 1. Successful treatment of a refractory skin ulcer in chronic cutaneous GvHD after allogeneic HSCT with split-thickness skin allografting from the stem cell donor.
    Ammer J; Prantl L; Holler B; Landfried K; Wolff D; Karrer S; Andreesen R; Holler E
    Bone Marrow Transplant; 2012 Oct; 47(10):1368-9. PubMed ID: 22343673
    [No Abstract]   [Full Text] [Related]  

  • 2. Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients.
    Lamby P; Wolff D; Mielke S; Grigoleit GU; Ljungman P; Hilgendorf I; Holler E; Holler B; Weber D; Herr W; Schiltz D; Klein S; Graf S; Bjornhagen-Safwenberg V; Dolderer J; Prantl L
    Ann Hematol; 2019 Aug; 98(8):1867-1875. PubMed ID: 30993415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease.
    Pusic I; Pavletic SZ; Kessinger A; Tarantolo SR; Bishop MR
    Bone Marrow Transplant; 2002 Apr; 29(8):709-10. PubMed ID: 12180118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Ulcer by Cutaneous GvHD After Bone Marrow Transplantation Treated With Skin Allograft From HLA-Identical Donor: Case Report and Literature Review.
    Amendola F; Gazzola R; Lombardo M; Caminiti R; Dagna L; Baruffaldi-Preis FW
    Int J Low Extrem Wounds; 2016 Jun; 15(2):139-41. PubMed ID: 27009789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
    Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation].
    Chen Y; Xu Y; Zhu Y; Fu G; Liu Y; Peng J; Fu B; He Q; Wu D; Li X; Zhao X; Chen F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 36(9):859-64. PubMed ID: 21946205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-engraftment graft-versus-host disease after allogeneic hematopoietic cell transplantation for acute leukemia.
    Lee JH; Lee JH; Kim DY; Yun SC; Kim SD; Choi Y; Lee YS; Kang YA; Jeon MJ; Seol M; Lee KH
    Eur J Haematol; 2011 Aug; 87(2):172-81. PubMed ID: 21599753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic split-skin grafting in stem cell transplanted patients.
    Berg JO; Vindeløv L; Schmidt G; Drzewiecki KT
    J Plast Reconstr Aesthet Surg; 2008 Dec; 61(12):1512-5. PubMed ID: 18158277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
    Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic skin grafting for extensive skin chronic graft-versus-host disease.
    Kondo S; Tamura K; Makino S; Takamatsu Y
    Int J Hematol; 1994 Aug; 60(2):151-5. PubMed ID: 7948965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
    Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S;
    Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
    Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of a severe extensive cutaneous chronic GVHD after allo-HSCT using glycerolyzed skin allografts and cultured epidermis from the same donor.
    Crocchiolo R; Nicolini FE; Sobh M; Ducastelle-Lepretre S; Labussiere H; Dubois V; Auxenfans C; Mojallal A; Damour O; Braye F; Michallet M
    Bone Marrow Transplant; 2011 Aug; 46(8):1153-5. PubMed ID: 21042311
    [No Abstract]   [Full Text] [Related]  

  • 18. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet gel for treatment of mucocutaneous lesions related to graft-versus-host disease after allogeneic hematopoietic stem cell transplant.
    Picardi A; Lanti A; Cudillo L; Cerretti R; Dentamaro T; De Angelis G; Ferraro A; Di Veroli A; Adorno G; Arcese W;
    Transfusion; 2010 Feb; 50(2):501-6. PubMed ID: 19821947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
    Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.